The regulator agreed to allow Sangamo Therapeutics to use data to seek accelerated approval for its Fabry gene therapy ...

Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...

Novo Nordisk has nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding list, which ...

In the battle over drug prices, one sector of the healthcare industry has risen above all the players as the boogeyman: ...

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

Alto Neuroscience’s depression treatment failed to beat placebo just nine months after the biotech went public. The stunning ...

Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...

For biopharma executives who are between roles, navigating the transitionary time can be challenging. However, they can ...

Monday’s lawsuits from Eli Lilly are the first to be filed by the pharma since the regulator officially removed tirzepatide ...

The regulator cited deficiencies at a third-party manufacturing facility. Camurus is seeking approval for its ...

Nucleus RadioPharma’s two sites are meant to help address the industry’s lack of manufacturing and development capabilities, ...